EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub‐Saharan African Populations

David Twesigomwe iD, Britt I Drögemöller iD, Galen E B Wright iD, Clement Adebamowo iD, Godfred Agongo iD, Palwendé R Boua iD, Mogomotsi Matshaba iD, Maria Paximadis iD, Michèle Ramsay iD, Gustave Simo iD, Martin C Simuunza iD, Caroline T Tiemessen iD and 2 more

Clinical Pharmacology & Therapeutics · 2024-03 · 115 (3) · 576-594

DOI: 10.1002/cpt.3124 ↗

At a glance

Journal article in Clinical Pharmacology & Therapeutics, published online on 2023-12-20. Written by David Twesigomwe and 13 co-authors. Institution: Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Major MEDLINE topics: Pharmacogenetics, Nicotine. Cited 11 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY 4.0). Funded by: NHGRI NIH HHS, Wellcome Trust, National Human Genome Research Institute.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Genetic variation in CYP2B6 and CYP2A6 is known to impact interindividual response to antiretrovirals, nicotine, and bupropion, among other drugs. However, the full catalogue of clinically relevant pharmacogenetic variants in these genes is yet to be established, especially across African populations. This study therefore aimed to characterize the star allele (haplotype) distribution in CYP2B6 and CYP2A6 across diverse and understudied sub‐Saharan African (SSA) populations. We called star alleles from 961 high‐depth full genomes using StellarPGx, Aldy, and PyPGx. In addition, we performed CYP2B6 and CYP2A6 star allele frequency comparisons between SSA and other global biogeographical groups represented in the new 1000 Genomes Project high‐coverage dataset ( n = 2,000). This study presents frequency information for star alleles in CYP2B6 (e.g., *6 and *18 ; frequency of 21–47% and 2–19%, respectively) and CYP2A6 (e.g., *4 , *9 , and *17 ; frequency of 0–6%, 3–10%, and 6–20%, respectively), and predicted phenotypes (for CYP2B6), across various African populations. In addition, 50 potentially novel African‐ancestry star alleles were computationally predicted by StellarPGx in CYP2B6 and CYP2A6 combined. For each of these genes, over 4% of the study participants had predicted novel star alleles. Three novel star alleles in CYP2A6 (* 54 , * 55 , and * 56 ) and CYP2B6 apiece, and several suballeles were further validated via targeted Single‐Molecule Real‐Time resequencing. Our findings are important for informing the design of comprehensive pharmacogenetic testing platforms, and are highly relevant for personalized medicine strategies, especially relating to antiretroviral medication and smoking cessation treatment in Africa and the African diaspora. More broadly, this study highlights the importance of sampling diverse African ethnolinguistic groups for accurate characterization of the pharmacogene variation landscape across the continent.

Subjects

MeSH terms (MEDLINE)

PharmacogeneticsNicotineHumansCytochrome P-450 CYP2B6Cytochrome P-450 CYP2A6Gene FrequencyAfrica South of the SaharaGenotypeAlleles

Substances

Cytochrome P-450 CYP2B6Cytochrome P-450 CYP2A6NicotineCYP2B6 protein, humanCYP2A6 protein, human

Authors and institutions

  • Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Division of Human Genetics, National Health Laboratory Service, and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Neuroscience Research Program, Kleysen Institute for Advanced Medicine, Winnipeg Health Sciences Centre and Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Department of Pharmacology and Therapeutics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Institute for Human Virology, Abuja, Nigeria.

ORCID profiles: David Twesigomwe, Britt I Drögemöller, Galen E B Wright, Clement Adebamowo, Godfred Agongo, Palwendé R Boua, Mogomotsi Matshaba, Maria Paximadis, Michèle Ramsay, Gustave Simo, Martin C Simuunza, Caroline T Tiemessen, Zané Lombard, Scott Hazelhurst

Funding

  • NHGRI NIH HHS
  • Wellcome Trust
  • National Human Genome Research Institute
  • Bill and Melinda Gates Foundation

Cite

APA

Twesigomwe, D., Drögemöller, B. I., Wright, G. E. B., Adebamowo, C., Agongo, G., Boua, P. R., Matshaba, M., Paximadis, M., Ramsay, M., Simo, G., Simuunza, M. C., Tiemessen, C. T., Lombard, Z., & Hazelhurst, S. (2024). Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub‐Saharan African Populations. Clinical Pharmacology & Therapeutics, 115(3), 576-594. https://doi.org/10.1002/cpt.3124

Vancouver

Twesigomwe D, Drögemöller BI, Wright GEB, Adebamowo C, Agongo G, Boua PR, et al. Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub‐Saharan African Populations. Clinical Pharmacology & Therapeutics. 2024;115(3):576-594. doi:10.1002/cpt.3124

BibTeX
@article{Twesigomwe2024,
  author = {Twesigomwe, David and Drögemöller, Britt I and Wright, Galen E B and Adebamowo, Clement and Agongo, Godfred and Boua, Palwendé R and Matshaba, Mogomotsi and Paximadis, Maria and Ramsay, Michèle and Simo, Gustave and Simuunza, Martin C and Tiemessen, Caroline T and Lombard, Zané and Hazelhurst, Scott},
  title = {Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub‐Saharan African Populations},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  volume = {115},
  number = {3},
  pages = {576--594},
  doi = {10.1002/cpt.3124}
}
Start for free →